High Risk Neuroblastoma Study 1.7 of SIOP-Europe – SIOPEN
Lead Investigator: Study Ruth Ladenstein / Austria
Lead Investigator: Infant issues Adela Canete / Spain
Lead Investigator: Induction
פרוטוקולים נוירובלסטומה
Long term continuous infusion ch14.18/CHO plus s.c. aldesleukin – IL-2
10:08
אין תגובות
Protocol Number: 012010
Status: Version 3.0
Prospective, open label, randomized phase II trial to assess a multimodal molecular targeted therapy in children, adolescent and young adults with relapsed or refractory high-risk neuroblastoma
10:51
אין תגובות
Study drugs: Rapamycin, Dasatinib, Temozolomide, Irinotecan
Version: 4.0
Status: Final
Date: 03.01.2014
Rapid COJEC versus standard induction therapies for high-risk neuroblastoma Protocol
16:42
אין תגובות
Peinemann F, Tushabe DA, Berthold F
Treatment of children over the age of one year with unresectable localised neuroblastoma without MYCN amplification: Results of the SIOPEN study
16:20
אין תגובות
Kohler, J.A. et al.
European Journal of Cancer , Volume 49 , Issue 17 , 3671 - 3679
New Strategies in Refractory and Recurrent Neuroblastoma: Translational Opportunities to Impact Patient Outcome
9:58
אין תגובות
Kristina A. Cole and John M. Maris
Clin Cancer Res; 18(9); 2423–8. 2012 AACR.
DOI: 10.1158/1078-0432.CCR-11-1409 Published May 2012
New Aspects of Neuroblastoma Treatment: ASPHO 2011 Symposium Review
16:39
אין תגובות
Zage, P. E., Louis, C. U. and Cohn, S. L. (2012), Pediatr. Blood Cancer, 58: 1099-1105.
European Low and Intermediate Risk Neuroblastoma
10:32
אין תגובות
Study Group 1:
A phase III randomised prospective multi-centre trial
Study Groups 2-10 and Neonatal Suprarenal Masses:
Non-blinded,
Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children’s Oncology Group Study
10:35
אין תגובות
Bagatell R, London WB, Wagner LM, et al.
J Clin Oncol. 2010;29(2):208-13.
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
16:57
אין תגובות
Alice L. Yu, M.D., Ph.D et al.,
N Engl J Med 2010; 363:1324-1334
